$0.08 EPS Expected for Luminex Corporation (LMNX)

October 2, 2018 - By Winifred Garcia

Luminex Corporation (NASDAQ:LMNX) Logo

Analysts expect Luminex Corporation (NASDAQ:LMNX) to report $0.08 EPS on October, 29.They anticipate $0.11 EPS change or 57.89 % from last quarter’s $0.19 EPS. LMNX’s profit would be $3.57 million giving it 91.66 P/E if the $0.08 EPS is correct. After having $0.15 EPS previously, Luminex Corporation’s analysts see -46.67 % EPS growth. The stock decreased 3.23% or $0.98 during the last trading session, reaching $29.33. About 209,807 shares traded. Luminex Corporation (NASDAQ:LMNX) has risen 49.24% since October 2, 2017 and is uptrending. It has outperformed by 33.62% the S&P500.

Luminex Corporation (NASDAQ:LMNX) Ratings Coverage

Among 2 analysts covering Luminex (NASDAQ:LMNX), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Luminex had 2 analyst reports since May 7, 2018 according to SRatingsIntel. The stock of Luminex Corporation (NASDAQ:LMNX) earned “Neutral” rating by Citigroup on Monday, July 23. On Monday, May 7 the stock rating was upgraded by Deutsche Bank to “Hold”.

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and life sciences industries worldwide. The company has market cap of $1.31 billion. The company??s products include Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; Verigene system, an automated multiplex-capable system; and ARIES system, a sample to answer real-time PCR platform. It has a 38.69 P/E ratio. It also offers MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; ARIES cassettes that are self-contained assay consumables; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; respiratory viral family of products to identify the causative agent for respiratory infections; and gastrointestinal pathogen panel assays to identify the pathogens causing infectious gastroenteritis.

Luminex Corporation (NASDAQ:LMNX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: